Isotopically substituted proton pump inhibitors

Details Isotopically substituted proton pump inhibitors Isotopically substituted proton pump inhibitors

2007-12-12

2009-10-13

Morris, Patricia L (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S118000

Reexamination Certificate

active

07601737

ABSTRACT:
The invention relates to compounds of formula 1and formula 10and to compositions comprising these compounds and methods of treating gastrointestinal disorders by administering these compounds.

REFERENCES:
patent: 4758579 (1988-07-01), Kohl et al.
patent: 6818200 (2004-11-01), Foster et al.
patent: 6872408 (2005-03-01), Bell
patent: 6881734 (2005-04-01), O'Neill et al.
patent: 7317039 (2008-01-01), Alken
patent: 2007/0082929 (2007-04-01), Gant et al.
patent: 44 27 690 (1996-02-01), None
patent: 0 005 129 (1979-10-01), None
patent: 0 166 287 (1986-01-01), None
patent: 0 174 726 (1986-03-01), None
patent: 0 254 588 (1988-01-01), None
patent: 0 268 956 (1988-06-01), None
patent: 2 036 948 (1993-06-01), None
patent: 92/08716 (1992-05-01), None
patent: 03/050101 (2003-06-01), None
patent: 2004/052881 (2004-06-01), None
patent: 2007/041630 (2007-04-01), None
Vippagunta et al., “Crystalline Soilid”, Advanced Drug Delivery Reviews 48 (2001) 3-26.
Guillory in Brittain ed., “Polymorphism, etc.,” NY: Marcel Dekker, Inc., 1999, 1-2, 183-226.
Stenhoff, H., et al., “Determination of the enantiomers of omeprazole in blood plasma by normal-phase liquid chromatography and detection by atmospheric pressure ionization tandem mass spectrometry”, Journal of Chromatography B, vol. 734, pp. 191-201, (1999).
Tolonen, A., et al., “A simple method for differentiation of monoisotopic drug metabolites with hydrogen-deuterium exchange liquid chromatography/electrospray mass spectrometry”, European Journal of Pharmaceutical Sciences, vol. 25, pp. 155-162, (2005).
Helander, H.F., et al., “Localization of omeprazole and metabolites in the mouse”, Scand J Gastroentrol, vol. 20, Suppl. 108, pp. 95-104, (1985).
Sjöström, J.E., et al., “In Vitro Antibacterial Activity of Omeprazole and Its Selectivity for Helicobacter spp. Are Dependent on Incubation Conditions”, Antimicrobial Agents and Chemotherapy, vol. 40, No. 3, pp. 621-626, (1996).
Tanaka, M., et al., “Differential Stereoselective Pharmacokinetics of Pantoprazole, a Proton Pump Inhibitor in Extensive and Poor Metabolizers of Pantoprazole—A Preliminary Study”, Chirality, vol. 9, pp. 17-21, (1997).
Hoffmann, K-J., “Identification of the Main Urinary Metabolites of Omeprazole after an Oral Dose to Rats and Dogs”, Drug Metabolism and Disposition, vol. 14, No. 3, pp. 341-348, (1986).
Helander, H.F., et al., “Localization of omeprazole in the mouse”, Gastroenterology, vol. 86, p. 1109, (1984).
Brändström, A., et al., “Chemical Reactions of Omeprazole and Omeprazole Analogues. III. Protolytic Behaviour of Compounds in the Omeprazole System”, Acta Chemica Scandinavica, vol. 43, pp. 569-576, (1989).

Affiliated with

Also associated with

Rating

Isotopically substituted proton pump inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Isotopically substituted proton pump inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isotopically substituted proton pump inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4123859